{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T11:40:08Z","timestamp":1759146008043},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transactions of the Royal Society of Tropical Medicine and Hygiene"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.trstmh.2010.11.004","type":"journal-article","created":{"date-parts":[[2010,12,24]],"date-time":"2010-12-24T09:19:37Z","timestamp":1293182377000},"page":"61-67","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacovigilance methods in public health programmes: the example of miltefosine and visceral leishmaniasis"],"prefix":"10.1093","volume":"105","author":[{"given":"Nilima","family":"Kshirsagar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Ferner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byron Alfredo Arana","family":"Figueroa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hashim","family":"Ghalib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janis","family":"Lazdin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"10.1016\/j.trstmh.2010.11.004_bib0005","unstructured":"WHO. The importance of pharmacovigilance\u2014safety monitoring of medicinal products. Geneva: World Health Organization; 2002."},{"key":"10.1016\/j.trstmh.2010.11.004_bib0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2165\/00002018-200932040-00005","article-title":"Vaccines and Guillain\u2013Barr\u00e9 Syndrome","volume":"32","author":"Haber","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.trstmh.2010.11.004_bib0015","first-page":"345","article-title":"Visceral leishmaniasis\u2014current therapeutic modalities","volume":"123","author":"Sunder","year":"2006","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.trstmh.2010.11.004_bib0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1179\/000349802125000466","article-title":"Immunochromatographic strip-test detection of anti-K39 antibody in Indian visceral leishmaniasis","volume":"96","author":"Sundar","year":"2002","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.trstmh.2010.11.004_bib0025","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1086\/342057","article-title":"Noninvasive management of Indian visceral leishmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit","volume":"35","author":"Sundar","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trstmh.2010.11.004_bib0030","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for visceral Leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trstmh.2010.11.004_bib0035","unstructured":"WHO. Regional strategic framework for elimination of kala-azar from the South-East Asia Region (2005-2015). New Delhi, India: World Health Organization Regional Office for South-East Asia; 2005. SEA-VBC-85.(Rev. 1)."},{"key":"10.1016\/j.trstmh.2010.11.004_bib0040","unstructured":"National Vector Borne Disease Control Programme, Government of India. Guidelines on use of miltefosine. Delhi, India: National Vector Borne Disease Control Programme, Government of India. http:\/\/nvbdcp.gov.in\/Doc\/Guidelines%20on%20miltefosine.pdf [accessed 26 October 2010]."},{"issue":"Suppl 1","key":"10.1016\/j.trstmh.2010.11.004_bib0045","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.trstmh.2006.02.010","article-title":"Development of miltefosine as an oral treatment for leishmaniasis","volume":"100","author":"Sindermann","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.trstmh.2010.11.004_bib0050","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1136\/bmj.311.7005.619","article-title":"Probability of adverse events that have not yet occurred: a statistical reminder","volume":"311","author":"Eypasch","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.trstmh.2010.11.004_bib0055","unstructured":"European Medicines Agency. The rules governing medicinal products in the European Union. Vol. 9A. London, UK: European Medicines Agency; 2008."},{"key":"10.1016\/j.trstmh.2010.11.004_bib0060","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/0277-9536(88)90380-2","article-title":"Pharmaceuticals and health policy: an Indian example","volume":"27","author":"Stoker","year":"1988","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.trstmh.2010.11.004_bib0065","first-page":"105","article-title":"Can visceral leishmaniasis be eliminated from Asia?","volume":"45","author":"Joshi","year":"2008","journal-title":"J Vector Borne Dis"},{"key":"10.1016\/j.trstmh.2010.11.004_bib0070","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2165\/00002018-200528070-00008","article-title":"The pharmacovigilance system in India","volume":"28","author":"Kshirsagar","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.trstmh.2010.11.004_bib0075","unstructured":"WHO. A practical handbook on the pharmacovigilance of antimalarial medicines. Geneva: World Health Organization; 2008."},{"key":"10.1016\/j.trstmh.2010.11.004_bib0080","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1475-2875-7-107","article-title":"Monitoring antimalarial safety and tolerability in clinical trials: a case study from Uganda","volume":"7","author":"Staedke","year":"2008","journal-title":"Malar J"},{"key":"10.1016\/j.trstmh.2010.11.004_bib0085","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/pds.1907","article-title":"Adverse drug reactions to antiretroviral therapy (ART): an experience of spontaneous reporting and intensive monitoring from ART centre in India","volume":"19","author":"Modayil","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.trstmh.2010.11.004_bib0090","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-3156.2007.01823.x","article-title":"Malaria deaths as sentinel events to monitor healthcare delivery and antimalarial drug safety","volume":"12","author":"Mehta","year":"2007","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.trstmh.2010.11.004_bib0095","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/1099-1557(200005\/06)9:3<235::AID-PDS495>3.0.CO;2-O","article-title":"Adverse drug reaction (ADR) monitoring in India and the postal survey as a useful tool for ADR detection","volume":"9","author":"Gogtay","year":"2000","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.trstmh.2010.11.004_bib0100","unstructured":"European Medicines Agency. ICH Topic E 6 (R1) Guideline for Good Clinical Practice. London: EMEA; July 2002. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002874.pdf [accessed 30 October 2010]."}],"container-title":["Transactions of the Royal Society of Tropical Medicine and Hygiene"],"original-title":[],"language":"en","deposited":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T17:38:46Z","timestamp":1497893926000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/trstmh\/article-lookup\/doi\/10.1016\/j.trstmh.2010.11.004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0035920310002427"],"URL":"https:\/\/doi.org\/10.1016\/j.trstmh.2010.11.004","relation":{},"ISSN":["0035-9203"],"issn-type":[{"type":"print","value":"0035-9203"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}